drugs
Post on 12-Dec-2015
213 Views
Preview:
DESCRIPTION
TRANSCRIPT
Drugs Used for Leukocyte Stimulation and Treatment (Stewart)
Treatment of Leukocyte, Lymphocyte and Platelet Disorders Neutropenia Thrombocytopenia Leukemia Lymphoma
Hematopoietic Growth Factors Glycoproteins that regulate proliferation and differentiation of
hematopoietic progenitor cells in the bone marrow Include:
o Erythropoietin o Granulocyte colony stimulating factor (G-CSF) o Granulocyte –macrophage colony stimulating factor (GM-
CSF) o Interleukins (IL-1 through IL-18) o Thrombopoietin
Mechanism of action o Many activate type I cytokine receptors o Regulate gene expression via the JAK/STAT pathway o Also stimulate activation of PI3K and Ras/MAPK pathways
Neutropenia Caused by:
o Bone marrow disorders o Peripheral disorders o Infection of gram
positive or gram negative bacteria or fungi
o Drugs Treatment:
o Discontinue causative drugs
o Infections are treated with broad spectrum antibiotics or antifungal agents
Antibiotics: Quinolones
(levofloxacin) Cephalosporins (cefepime)
Antifungal agents Voriconazole
Drugs Used for Leukocyte Stimulation and Treatment (Stewart)
o Administration of myeloid growth factors (GM-CSF, G-CSF)
GM-CSF/G-SCF increase neutrophils decrease infections
G-CSF Preparations
o Filgrastim (recombinant human G-CSF) Prepared in bacterial expression system Half life 2-7 hrs
o Pegfilgrastim (neulasta) (only have to give once) Polyetehylene glycol conjugate of filgrastim Longer half life than filgrastim
Route of administration:o IV or SC
Mechanism of actiono Activates G-CSF receptors o Increase proliferation and differentiation of neutrophil
progenitorso Increase phagocytic activity of mature neutrophils o Increase neutrophil survival o Mobilize hematopoietic stem cells
Clinical uses o Neutropenia
Congenital neutropenia Cyclic neutropenia Chemotherapy induced neutropenia Myelodysplasisa Aplastic anemia
o Neutrophil recovery following steam cell transplantation o Mobilization of PBSCs (stem cell transplantation)
G-CSF has best mobilization of PBSCs Side effects
o Bone pain o Splenic rupture (rare)
GM-CSF Preparations
o Sargramostim (recombinant human GM-CSF) Prepared in yeast expression system Serum half life of 2-7 yrs
Route of administrations:
Drugs Used for Leukocyte Stimulation and Treatment (Stewart)
o IV or SC Mechanism of Action/biological effects
o Stimulates proliferation and differentiation of granulocytic, erythroid and megakaryocyte progenitors
o Stimulates phagocytic activity of mature neutrophils o Increases neutrophil survival o Stimulate T cell proliferation (with IL-2)
Clinical uses (same as G-CSF) o Neutropenia
Congenital neutropenia Cyclic neutropenia Chemotherapy induced neutropenia Myelodysplasisa Aplastic anemia
o Neutrophil recovery following steam cell transplantation o Mobilization of PBSCs (stem cell transplantation)
Doesn’t work as well as G-CSF and has greater side effects
Side effects:o Fever o Malaise o Arthralgia’s o Myalgia o Capillary leak syndrome
Thrombocytopenia Treatment:
o Platelet transfusion Can cause adverse reaction in patients Doesn’t increase
platelet count in all patients
Not the best way o Administration of
recombinant IL-11 (oprelvekin) or thrombopoietin receptor agonists (romiplostim)
Better plan o Administration of IL-11 or
thrombopoietin receptor agonist (romiplostim)
Promote production of platelets
Drugs Used for Leukocyte Stimulation and Treatment (Stewart)
Recombinant human thrombopoietin induces formation of autoantibodies
IL-11 Endogenous form made in bone marrow by fibroblast and
stromal cells Recombinant form is Oprelvekin
o Produced in E.coli expression system o Half life is 7-8hrs (subcutaneously)
Route of administration: SC Mechanism of Action
o Activates IL-11 receptor o Stimulates growth of megakaryocytic progenitors o Increases circulating platelets
Clinical Uses o Prevent thrombocytopenia in patients receiving
chemotherapy (nonmyeloid cancers) Side effects:
o Fatigue o Headache o Dizziness o Cardiovascular effects (anemia, dyspnea, transient atrial
arrhythmias) IL-2
Endogenous IL-2 made by activated T- cells Recombinant form known as aldesleukin Mechanism of action
o Induces T cell proliferation and differentiation o Increases NK cells
Clinical uses o Renal cell cancer o Metastatic melanoma
Leukemia (Acute and Chronic)
ALL treatment Strategy Induction therapy
o Vincristine o Prednisone o L-asparaginase with
or without an anthracycline
Drugs Used for Leukocyte Stimulation and Treatment (Stewart)
o Supportive care – blood and platelet transfusions, antibiotics, filgrastim
Consolidation/intensification therapy o Cyclophosphamide o Cytararbine o 6-mercaptopurine
Maintenance therapy o methotrexate o 6-mercaptopurine
CNS prophylaxis (intrathecal methotrexate)
AML Treatment Strategy Induction Chemotherapy
o Cytarabine + an anthracyclin (idarubicin or daunorubicin) Supportive care- platelet transfusions, filgrastim,
and antibiotics Intrathecal chemotherapy (cytarabine or
methotrexate) Consolidation chemotrheapy
o Once remission achieved o Involving cytabarine
Allogenic bone marrow transplantation o <55 years old
CML Treatment Strategy First line therapy include tyrosine kinase inhibitors that target
Bcr-Abl: Imatinib (targets Bcr-Abl, c-kit and PDGFR) Dasatinib (targets Bcr-Abl, Src, c-kit and PDGFR- α) Nilotinib (targets Bcr-Abl, c-kit and PDGFR- β)
o Route of administration – oral o Side effects:
Nausea Vomiting Fluid retention Diarrhea Myalgias Congestive heart failure
Additional CML treatment options include:o Interferon αo Busulfan o Hydroxureao Cytarabine (high dose) o Vincristine and prednisone -/+ anthrracycline
Drugs Used for Leukocyte Stimulation and Treatment (Stewart)
Choice of therapy depends on disease pahse Only consistently curative option is allogenic bone marrow
transplantation or stem cell transplantation
CLL Treatment Strategy (Stages I-IV) Watchful waiting (asymptomatic) Alkylating agents
o Chlorambucil (in combination with prednisone) o Cyclophosphamide (in COP or CHOP) o Bendamustine
Purine analogs o Fludarabine
Monoclonal antibody targeted therapies o Rituximab
Mechanism of action Binds to CD20 on malignant B lymphocytes Stimulates cell death
Route of administration – intravenous Side effects – hypersensitivity, myelosuppresion Can be combined with other drugs (CHOP,
fludarabine) o Alemtuzumab
Humanized mAb that targets CD52 Treatment fro B cell CLL that is refractory to
alkylating agents or fludarabine Mechanism of action- antibody driven cell
lysis/death
Treatment Strategy for Hodgkin’s Lymphoma Stage I and IIa disease
o Combination chemotherapy (ABVD)+ involved filed radiation therapy
Stage III and IV disease o 4 cycles of ABVD or 12 weeks of Stanford V o Radiation therapy may follow Stanford V
Drugs Used for Leukocyte Stimulation and Treatment (Stewart)
Treatment Strategy for Recurrent Hodgkin’s Lymphoma
Recurrence following radiation chemotherapy Recurrence following chemotherapy stem cell transplant
Treatment Strategy for Indolent Non- Hodgkin’s Lymphoma (Follicular)
Disease Stage Treatment Options
Indolent Stage I and Contiguous Stage II
1. Radiation Therapy2. Rituximab (-/+ chemotherapy)3. Watchful waiting
Indolent, Noncontinguous Stage II/III/IV
1. Watchful waiting2. Rituximab3. Purine Nucleoside analogs
(Fludarabine)4. Alkylating Agents (-/+
prenisone)5. Combination chemotherapy6. Ibritumomab tiuxetan and
tositumomabIndolent Recurrent 1. Chemotherpay
2. Rituximab3. Lenalidomide4. Ibritumomab tiuxetan and
tositumomab5. Palliative radiation therapy
Ibritumomab tiuxetan Mouse mAB against CD20 Labeled with Yttrium-90
Tositumomab Mouse mAb against CD20 Labeled with iodine 131
Drugs Used for Leukocyte Stimulation and Treatment (Stewart)
Treatment Strategy for Aggressive Non-Hodgkin’s Lymphoma (Diffuse)
Disease Stage Treatment Options
Aggressive Stage I and Contiguous Stage II
R-CHOP (-/+ radiation therapy)
Aggressive Noncontinguous Stage II/III/IV
1. R-CHOP2. Combination chemotherapy
(CHOP and others)Aggressive Recurrent 1. bone marrow or stem cell
transplantation2. Retreatment with rituximab,
ibritumomab tiuxetan and tositumomab
3. palliative radiation therapy
Types of Stem Cell Transplantation
Autologous o hematopoietic stem cells from patients peripheral blood o mobilized using G-CSF (filgrastim) o isolated by centrifugation and cryopreserved
Allogenic o Hematopoietic stem cells from appropriate donor o Donor must be matched with patient at HLA locus
Immunosuppressive Drugs
Drugs Used for Leukocyte Stimulation and Treatment (Stewart)
Used to reduce occurrence or impact of exaggerated/inappropriate immune responses
Common clinical uses are for solid organ and bone marrow transplantation and autoimmune disorders
Immunosuppression in patients with aplastic anemia Immunosuppressive drugs reduce T cell driven immune
response Used in patients that cannot undergo bone or blood marrow
transplant Option1 – anti-thymocyte globulin +cyclosporine
o Cyclosporine inhibits calcineurin reduces the production of IL-2 and IFNγ by
activated cells Option 2- cyclophosphamide
o Alkylating agent that destroys proliferating lymphoid cells
top related